Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 6Recurrence 2Leukemia 2Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Imatinib Mesylate 28nilotinib 21Cytarabine 8Cyclophosphamide 8Methotrexate 7Peripheral Blood Stem Cell Transplantation 6Interferon-alpha 6Hydroxyurea 6bosutinib 5asciminib 5Whole-Body Irradiation 5Mycophenolic Acid 5Tacrolimus 4Dasatinib 4Busulfan 4peginterferon alfa-2a 3fludarabine phosphate 3fludarabine 3Radiotherapy 3Cyclosporine 3sargramostim 2ponatinib 2Sirolimus 2Idarubicin 2Etoposide 2BID protein, human 2thymoglobulin 1peginterferon alfa-2b 1pegaspargase 1olverembatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Homoharringtonine × Clear all
NCT00004933 2016-07-04

Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

Alliance for Clinical Trials in Oncology

Phase 3 Terminated
5 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡